Return to Travel in the Coronavirus Disease 2019 Pandemic Recovery Period and Implications for Imported Malaria: Reinforcing Prevention, Early Diagnosis, and Appropriate Treatment of Malaria

Return to international travel in the COVID-19 pandemic recovery period is expected to increase the number of patients with imported malaria in the United States (US). Malaria prevention in travelers and preparedness for timely diagnosis and appropriate treatment are key to minimize imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available from commercial distributors in the US for the treatment of severe malaria. Hospitals and pharmacists should have a plan for malaria treatment, including stocking artemether-lumefantrine for uncomplicated malaria, and stocking or planning for rapid procurement of IVAS for the treatment of severe malaria.

Automated summary

The increase in international travel during the COVID-19 pandemic recovery period is expected to lead to an increase in imported malaria cases in the US. Prevention, timely diagnosis, and appropriate treatment are crucial in minimizing imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available for severe malaria treatment in the US. Hospitals and pharmacists should have a malaria treatment plan that includes stocking artemether-lumefantrine for uncomplicated malaria and ensuring access to IVAS for severe cases.